阿尔兹海默病发病机制的研究进展及临床用药

摘要/Abstract

摘要： 阿尔兹海默病(Alzheimer′s disease， AD)是一种常见的中枢神经系统退行性疾病，主要发病于65岁以上的老年人群，通常又被称为原发性老年痴呆症。临床上常表现为记忆功能障碍、认知功能缺失、语言功能下降等，严重影响人们的生活与健康。AD的发病机制尚不明确，其被学界广泛公认的学说有：Aβ沉积及毒性作用学说、Tau蛋白过度磷酸化假说、胆碱能功能缺损学说、兴奋性氨基酸毒性学说以及炎症反应学说等。目前仍未有效的药物来预防、改善或逆转AD的发生，因此研发新型、有效的AD治疗药物成为全球关注的热点。本文对阿尔兹海默病发病机制的最新研究进展及临床用药作一综述，为进一步研究AD提供数据参考。

Abstract: Alzheimer′s disease (AD) is a common central nervous system degenerative disease， mainly affected by the elderly over 65 years old. Often referred to as primary AD. Clinically， it often manifests as memory dysfunction， lack of cognitive function， and decreased language function， which affect people′s life and health. The mechanisms of AD are still unclear， and its doctrines recognized by a wide range of scholars around the world are：Aβ deposition and toxicity theory， Tau protein hyperphosphorylation theory， cholinergic function deficit theory， excitatory amino acid toxicity theory， inflammatory response theory， etc. There are still no effective drugs to prevent， improve or reverse the occurrence of AD. Therefore， the development of new and effective therapeutic drugs has become a global hot spot. In this paper， the latest research progress and clinical drug use of AD pathology are reviewed in detail， which provides a theoretical basis for further research on AD.

王威丽,宋沧桑. 阿尔兹海默病发病机制的研究进展及临床用药[J]. .

Wang Weili and. Recent Advances in the Pathogenesis of Alzheimer′s Disease and Clinical Medication[J]. .

参考文献

[1]Alzheimer′s Disease International. Alzheimer′s Disease International calls for action to tackle dementia crisis[M]. London， 31 August 2018. [2]Toledo JB， Zetterberg H， van Harten AC， et al. Alzheimer′s disease cerebrospinal fluid biomarker in cognitively normal subjects [J]. Brain， 2015， 138(9)：2701-2715. [3]Hampel H， Toschi N， Babiloni C， et al. Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology [J]. J Alzheimers Dis， 2018， 64(1)：S47-S105. [4]Ossenkoppele R， Schonhaut DR， Schll M， et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer′s disease [J]. Brain， 2016， 139(5)：1551-1567. [5]Weiner MW， Veitch DP， Aisen PS， et al. 2014 Update of the Alzheimer′s Disease Neuroimaging Initiative：A review of papers published since its inception [J]. Alzheimers Dement， 2015， 11(6)：e1-120. [6]Roch JM， Masliah E， Roch-Levecq AC， et al. Increase of synaptic density and memory retention by a peptide representing the trophic domain of the amyloid beta/A4 protein precursor [J]. Proc Natl Acad Sci USA， 1994， 91(16)：7450-7454. [7]Roher AE， Kokjohn TA， Clarke SG， et al. APP/Aβ structural diversity and Alzheimer′s disease pathogenesis [J]. Neurochem Int， 2017， 110：1-13. [8]Wang X， Zhou X， Li G， et al. Modifications and Trafficking of APP in the Pathogenesis of Alzheimer′s Disease [J]. Front Mol Neurosci， 2017， 10：294. [9]Heneka MT， Carson MJ， El Khoury J， et al. Neuroinflammation in Alzheimer′s disease [J]. Lancet Neurol， 2015， 14(4)：388-405. [10]Chen GF， Xu TH， Yan Y， et al. Amyloid beta：structure， biology and structure-based therapeutic development [J]. Acta Pharmacol Sin， 2017， 38 (9)：1205-1235. [11]Ferreira ST， Klein WL. The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer′s disease [J]. Neurobiol Learn Mem， 2011， 96(4)：529-543. [12]Krivinko JM， Erickson SL， Ding Y， et al. Synaptic Proteome Compensation and Resilience to Psychosis in Alzheimer′s disease [J]. Am J Psychiatry， 2018， 17080858. [13]Silva SV， Haberl MG， Zhang P， et al. Early synaptic deficits in the APP/PS1 mouse model of Alzheimer′s disease involve neuronal adenosine A2A receptors [J]. Nat Commun， 2016， 7：11915. [14]Jadhav S， Cubinkova V， Zimova I， et al. Tau-mediated synaptic damage in Alzheimer′s disease [J]. Translational neuroscience， 2015， 6(1)：214-226. [15]Gulisano W， Melone M， Palmeri A， et al. The effect of amyloid-β peptide on synaptic plasticity and memory is influenced by different isoforms，concentrations， and aggregation status [J]. Neurobiol Aging， 2018， 71：51-60. [16]Fernandez-Martos CM， King AE， Atkinson RA， et al. Neurofilament light gene deletion exacerbates amyloid， dystrophic neurite， and synaptic pathology in the APP/PS1 transgenic model of Alzheimer′s disease [J]. Neurobiol Aging， 2015， 36：2757-2767. [17]Li S， Yan Y， Jiao Y， et al. Neuroprotective Effect of Osthole on Neuron Synapses in an Alzheimer′s disease Cell Model via Upregulation of MicroRNA-9 [J]. Journal of Molecular Neuroscience， 2016， 60(1)：71-81. [18]唐智，单可人，官志忠. 神经型尼古丁乙酰胆碱受体在阿尔茨海默病发病机制中的作用[J]. 中国老年学杂志，2009， 29 (12)：1589-1591. [19]Lewczuk P， Easelmann H， Bibl M， et al. Tau protein phospho-rylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer′s disease：original data and review of the literature [J]. J Mol Neurosci， 2004， 23(1-2)：115-122. [20]Yao YJ， Liang K， Jiao YN， et al. Osthole promotes differentiation into neurons and reduces neuronal apoptosis via Wnt/β-catenin signaling pathway in APP transduced neural stem cells [J]. Chinese Pharmacological Bulletin， 2015. [21]Wang P， Wang Q， Yang B， et al. The Progress of Metabolomics Study in Traditional Chinese Medicine Research [J]. American Journal of Chinese Medicine， 2015， 43 (7)：1281. [22]许国旺，路鑫，杨胜利.代谢组学研究进展[J]. 中国医学科学院学报， 2007， 29(6)：701-711. [23]El-Desouki RAKM. New insights on Alzheimer′s disease [J]. Journal of Microscopy & Ultrastructure， 2014， 2(2)：57-66. [24]imic ′ G， Babic ′ LM， Wray S， et al. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer′s Disease and Other Tauopathies， and Possible Neuroprotective Strategies [J]. Biomolecules， 2016， 6 (1)：6. [25]Gong CX， Liu F，Inge GI， et al. Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation [J]. 2006， 9 (1)：1-12. [26]Gao YL， Wang N， Sun FR， et al. Tau in neurodegenerative disease [J]. Ann Transl Med， 2018， 6(10)：175. [27]Rahman A， Grundke-Iqbal I， Iqbal K. Phosphothreonine-212 of Alzheimer abnormally hyperphosphorylated tau is a preferred substrate of protein phosphatase-1 [J]. Neurochem Res， 2005， 30 ：277-287. [28]Min SW， Cho SH， Zhou Y， et al. Acetylation of tau inhibits its degradation and contributes to tauopathy [J]. Neuron， 2010， 67 ：953-966. [29]Cohen TJ， Guo JL， Hurtado DE， et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun， 2011， 2：252. [30]Irwin DJ， Cohen TJ， Grossman M， et al. Acetylated tau， a novel pathological signature in Alzheimer′s disease and other tauopathies [J]. Brain， 2012， 135 ：807-818. [31]Wang JZ， Grundke-Iqbal I， Iqbal K .Glycosylation of microtubule-associated protein tau：an abnormal posttranslational modification in Alzheimer′s disease [J]. Nat Med， 1996， 2 ：871-875. [32]Liu F， Iqbal K， Grundke-Iqbal I， et al. O-GlcNAcylation regulates phosphorylation of tau：a mechanism involved in Alzheimer′s disease [J]. Proc Natl Acad Sci USA， 2004， 101：10804-10809. [33]Reynolds MR， Reyes JF， Fu Y， et al. Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer′s disease and other tauopathies [J]. J Neurosci， 2006， 26 ：10636-10645. [34]Mori H， Kondo J， Ihara Y. Ubiquitin is a component of paired helical filaments in Alzheimer′s disease [J]. Science， 1987， 235 ：1641-644. [35]Cripps D， Thomas SN， Jeng Y， et al. Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48， Lys-11， and Lys-6 ubiquitin conjugation [J]. J Biol Chem， 2006， 281 ：10825-10838. [36]Dorval V， Fraser PE. Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein [J]. J Biol Chem， 2006， 281 ：9919-9924. [37]Lu PJ， Wulf G， Zhou XZ， et al. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein [J]. Nature， 1999， 399 ：784-788. [38]Nakamura K， Greenwood A， Binder L， et al. Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer′s disease [J]. Cell， 2012， 149：232-244. [39]Wischik CM， Novak M， Thogersen HC， et al. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease [J]. Proc Natl Acad Sci USA， 1988， 85 ：4506-4510. [40]Asaduzzaman M， Uddin M J， Kader M A， et al. In vitro acetylcholinesterase inhibitory activity and the antioxidant properties of Aegle marmelos leaf extract：implications for the treatment of Alzheimer′s disease [J]. Psychogeriatrics， 2014， 14(1)：1-10. [41]Mahlke JD， Boligon AA， Machado MM， et al. In vitro toxicity， antiplatelet and acetylcholinesterase inhibition of Buddleja thyrsoides Lam Leaves [J]. Natural product research， 2012， 26(23)：2223-2226. [42]A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer′s disease [J]. Dialogues in clinical neuroscience， 2000， 2(2)：111-128. [43]Carvajal FJ. Interactions of AChE with Aβ Aggregates in Alzheimer′s disease [J]. Frontiers in molecular neuroscience， 2011， 4：19. [44]Perry EK， Tomlinson BE， Blessed G， et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia [J]. BMJ， 1978， 2：1457-1459. [45]AMA，Revett TJ， Baker GB， et al.Glutamate system， amyloid ? peptides and tau protein：functional interrelationships and relevance to Alzheimer disease pathology [J]. J Psychiatry Neurosci， 2013， 38 (1)：6-23. [46]Basurto-Islas G， Luna-Muoz J， Guillozet-Bongaarts AL， et al. Accumulation of aspartic acid 421- and glutamic acid 391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease [J]. J Neuropathol Exp Neurol， 2008， 67(5)：470-483. [47]Tsang SW， Vinters HV， Cummings JL， et al. Alterations in NMDA receptor subunit densities and ligand binding to glycine recognition sites are associated with chronic anxiety in Alzheimer′s disease [J]. Neurobiol Aging， 2007， 29(10)：1524-1532. [48]Dysregulation of neural calcium signaling in Alzheimer disease， bipolar disorder and schizophrenia. Prion， 2013， 7(1)：2-13. [49]Tang CM， Dichter M， Morad M. Quisqualate activates a rapidly inactivating high conductance ionic channel in hippocampal neurons [J]. Science， 1989， 243(4897)：1474-1477. [50]Niswender CM， Conn PJ. Metabotropic glutamate receptors：physiology， pharmacology， and disease [J]. Annual review of pharmacology and toxicology， 2010， 50：295-322. [51]Brites D， Fernandes A. Neuroinflammation and depression：microglia activation， extracellular microvesicles and microRNA dysregulation [J]. Frontiers in cellular neuroscience， 2015， 9：476. [52]Babic ′ M， Svob trac D， Mück-eler D， et al. Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease. Croat Med J， 2014， 55(4)：347-365. [53]Takeda S， Sato N， Morishita R. Systemic inflammation， blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease：relevance to pathogenesis and therapy [J]. Front Aging Neurosci， 2014， 6：171. [54]Fuster-Matanzo A， Llorens-Martín M， Hernández F， et al. Role of neuroinflammation in adult neurogenesis and Alzheimer disease：therapeutic approaches [J]. Mediators Inflamm， 2013：260925. [55]Fiala M， Veerhuis R. Biomarkers of inflammation and amyloid-beta phagocytosis in patients at risk of Alzheimer disease [J]. Exp Gerontol， 2009， 45(1)：57-63. [56]Serrano-Pozo A， Gómez-Isla T， Growdon JH， et al.A phenotypic change but not proliferation underlies glial responses in Alzheimer disease[J]. Am J Pathol， 2013， 182(6)：2332-2344. [57]Holmes C， Cunningham C， Zotova E， et al. Proinflammatory cytokines， sickness behavior， and Alzheimer disease [J]. Neurology， 2011， 77(3)：212-218. [58]Cadenas E， Davies KJA. Mitochondrial free radical generation， oxidative stress， and aging [J]. Free Radical Biology and Medicine， 2000， 29(3-4)：222-230. [59]Reddy PH， Beal MF. Amyloid beta， mitochondrial dysfunction and synaptic damage：implications for cognitive decline in aging and Alzheimer′s disease [J]. Trends Mol Med， 2008， 14(2)：45-53. [60]吴彦霖. 抗老年痴呆药物971靶向保护线粒体的功能作用及机制研究[D]. 中国海洋大学， 2010. [61]章海燕. 痴呆发病相关的线粒体功能异常和治疗策略[C]. 2011全国老年痴呆与衰老相关疾病学术会议第三届山东省神经内科医师(学术)论坛论文汇编. 2011. [62]申屠路媚，牟艳玲. 线粒体功能障碍机制及其相关疾病研究进展[J]. 生命科学，2018，30(1)：87-93. [63]徐恩斌，张忠兵，谢渭芬.乙酰胆碱酯酶的研究进展[J]. 国外医学(生理、病理科学与临床分册)，2003(1)：73-75. [64]徐一峰，高之旭，汤洪川，等. 他克林治疗阿尔兹海默病：在中国的多中心双盲研究[J]. 中国新药与临床杂志， 2000，19(1)：7-10. [65]Giacobini， Ezio. Cholinesterase inhibitors：new roles and therapeutic alternatives [J]. Pharmacological research 50.4 (2004)：433-440. [66]Zhang Y， Li P， Feng J， et al. Dysfunction of NMDA receptors in Alzheimer′s disease [J]. Neurological Sciences， 2016， 37(7)：1039-1047. [67]Kitamura， S. Tolerability and efficacy of the long-term administration of memantine hydrochloride (Memary?) in patients with moderate to severe Alzheimer′s disease. Nihon Ronen Igakkai zasshi[J]. Japanese journal of geriatrics， 2014， 51：74-84.